You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ALK mutation

Showing 1 - 25 of 2,993
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in United States (NVL-655)

Recruiting
  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Orange, California
  • +13 more
Jan 31, 2023

Radiotherapy Side Effect, NSCLC, ALK Gene Mutation Trial in Stockholm (SBRT/SRS/radiation therapy)

Not yet recruiting
  • Radiotherapy Side Effect
  • +2 more
  • SBRT/SRS/radiation therapy
  • Stockholm, Sweden
    Karolinska University Hospital
Feb 16, 2023

ALK Gene Mutation, Lung Adenocarcinoma, Immunotherapy Trial in Changsha (Pembrolizumab Combined With Bevacizumab and

Not yet recruiting
  • ALK Gene Mutation
  • +2 more
  • Pembrolizumab Combined With Bevacizumab and Chemotherapy
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Jul 14, 2022

NSCLC Stage IIIB, ALK Gene Mutation Trial in Mexico City (Alectinib Oral Product)

Recruiting
  • Non-small Cell Lung Cancer Stage IIIB
  • ALK Gene Mutation
  • Alectinib Oral Product
  • Mexico City, Mexico
    Thoracic Oncology Unit and Personalized Medicine Laboratory, Ins
Jan 26, 2023

Lung Cancer, EGFR Gene Mutation, EGFR Trial in Charlottesville (Sensus Smartwatch Application, RX Cap, Fitbit Sense)

Recruiting
  • Lung Cancer
  • +3 more
  • Sensus Smartwatch Application
  • +3 more
  • Charlottesville, Virginia
    University of Virginia
Aug 26, 2022

NSCLC Trial in Guangzhou (Ensartinib, Bevacizumab)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Aug 4, 2022

PD-1 Antibody Plus Chemotherapy for TKI Failure Driver Gene

Recruiting
  • Non Small Cell Lung Cancer
    • Changsha, Hunan, China
      Yongchang Zhang
    Mar 9, 2022

    Either EML4-ALK Gene Rearrangements or T790M EGFR Mutation in

    Active, not recruiting
    • Carcinoma, Non-Small-Cell Lung
      • Hollywood, Florida
      • +1 more
      Sep 29, 2021

      Non Small Cell Lung Cancer, NSCLC, NSCLC Trial in Australia, Korea, Republic of, United States (TPX-0131)

      Active, not recruiting
      • Non Small Cell Lung Cancer
      • +5 more
      • Orange, California
      • +13 more
      Nov 7, 2022

      Advanced Malignant Tumor, ALK Fusion Protein Expression, ALK Gene Amplification Trial in Columbus (Brigatinib, Laboratory

      Withdrawn
      • Advanced Malignant Neoplasm
      • +10 more
      • Columbus, Ohio
        Ohio State University Comprehensive Cancer Center
      Feb 15, 2022

      Non Small Cell Lung Cancer Trial (Toripalimab, Toripalimab mimetic ())

      Not yet recruiting
      • Non Small Cell Lung Cancer
      • (no location specified)
      Feb 23, 2021

      NSCLC Trial in Seoul (Atezolizumab(Tecentriq), Pemetrexed, Bevacizumab)

      Recruiting
      • Non-small Cell Lung Cancer
      • Seoul, Gangnamgu, Korea, Republic of
        Samsung Medical Center
      Dec 27, 2021

      Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI

      Recruiting
      • Non-Small Cell Carcinoma of Lung, TNM Stage 4
      • +5 more
        • Aurora, Colorado
          University of Colorado, Cancer Center
        Nov 3, 2021

        Activating ALK Gene Mutation Negative, Activating EGFR Gene Mutation Negative, Activating ROS1 Gene Mutation Negative Trial in

        Completed
        • Activating ALK Gene Mutation Negative
        • +7 more
        • Counseling
        • +2 more
        • Philadelphia, Pennsylvania
          Sidney Kimmel Cancer Center at Thomas Jefferson University
        Sep 7, 2022

        NSCLC (NSCLC) Trial in Jinan (WX-0593 Tablets, chemo, Thoracic Radiation Therapy(TRT))

        Recruiting
        • Non-small Cell Lung Cancer (NSCLC)
        • WX-0593 Tablets
        • +2 more
        • Jinan, Shandong, China
          Shandong Cancer Hospital and Institute
        Apr 24, 2022

        Frequency, Clinical Phenotype and Genetic Analysis of Heritable

        Not yet recruiting
        • Renal Tumor Histology
        • +13 more
        • Gene test
        • Shanghai, Shanghai, China
          Ethics Committee of Shanghai Renji Hospital
        Sep 6, 2022

        Non Small Cell Lung Cancer, ALK Gene Mutation Trial in France (Brigatinib 180 MG, Carboplatin, Pemetrexed)

        Recruiting
        • Non Small Cell Lung Cancer
        • ALK Gene Mutation
        • Brigatinib 180 MG
        • +2 more
        • Angers, France
        • +31 more
        Aug 9, 2022

        Mediastinal Lymphadenopathy, Hilar Lymphadenopathy, Lymphoma Trial in Ancona (No suction EBUS-TBNA, Passive suction through

        Not yet recruiting
        • Mediastinal Lymphadenopathy
        • +9 more
        • No suction EBUS-TBNA
        • +2 more
        • Ancona, Italy
          Pulmonary Diseases Unit, Department of Immunoallergic and Respir
        May 25, 2022

        TNBC - Triple-Negative Breast Cancer, Triple Negative Breast Cancer, NSCLC Trial in United States (Sterotactic Body

        Active, not recruiting
        • TNBC - Triple-Negative Breast Cancer
        • +6 more
        • Sterotactic Body Radiotherapy/SBRT
        • Standard of care
        • Basking Ridge, New Jersey
        • +8 more
        Jul 26, 2022

        Nsclc, EGFR Activating Mutation, EGF-R Positive NSCLC Trial in Hong Kong (Pembrolizumab, Lenvatinib, Pemetrexed)

        Recruiting
        • Nsclc
        • +5 more
        • Hong Kong, Hong Kong
          Queen Mary Hospital
        Nov 25, 2021

        ALK Translocations in Serial Blood Samples From Non-Small Cell

        Enrolling by invitation
        • Lung Cancer
        • +3 more
        • Aarhus, Denmark
          Aarhus University Hospital
        Jan 30, 2021

        NSCLC (NSCLC) Trial in China (Capmatinib)

        Recruiting
        • Non-Small Cell Lung Cancer (NSCLC)
        • Xiamen, Fujian, China
        • +18 more
        Jan 27, 2023

        ALK Gene Rearrangement Positive, Non-Squamous Non-Small Cell Tumor of Lung Trial in Mexico City (Alectinib, Bevacizumab)

        Unknown status
        • ALK Gene Rearrangement Positive
        • Non-Squamous Non-Small Cell Neoplasm of Lung
        • Mexico City, Mexico
          Instituto Nacional de Cancerologia
        Feb 8, 2021

        NSCLC Stage IIIB, NSCLC Stage IV, EGFR Gene Mutation Trial in France (Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab,

        Recruiting
        • NSCLC Stage IIIB
        • +4 more
        • Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab
        • Carboplatin + Pemetrexed + Atezolizumab
        • Angers, France
        • +30 more
        Jun 7, 2021

        NUT Midline Carcinoma, Triple Negative Breast Cancer, NSCLC With Rearranged ALK Gene/Fusion Protein or KRAS Mutation Trial

        Completed
        Has Results
        • NUT Midline Carcinoma
        • +5 more
        • (no location specified)
        Jan 7, 2021